Similar Search Results

A Prospective View on European Pharmaceutical Research and Development: Policy Options to Reduce Fragmentation and Increase Competitiveness

Kanavos, Panos - In: PharmacoEconomics 13 (1998) 2, pp. 181-190

This article analyses 3 areas of policy that could reduce the fragmentation and improve the competitiveness of the European pharmaceutical sector. It argues that a potential solution to the issue of fragmentation of pharmaceutical research, development and innovation may be the development of...

Persistent link: https://www.econbiz.de/10005404808

Assessing the Impact of Global Price Interdependencies

Richter, Anke - In: PharmacoEconomics 26 (2008) 8, pp. 649-659

Documented launch delays and the ensuing debate over their underlying causes have focused on assessment from the individual country's perspective. Seen in a larger game theoretical framework this may cause problems, because although the countries see an individual game, the pharmaceutical firm...

Persistent link: https://www.econbiz.de/10005404838

Price Differentiation and Transparency in the Global Pharmaceutical Marketplace

Ridley, David B. - In: PharmacoEconomics 23 (2005) 7, pp. 651-658

Pharmaceutical manufacturers have increased the availability of their products and sometimes increased their own financial returns by charging lower prices outside of the US and by discounting to lower-income patients in the US. Examples include discounted HIV-AIDS drugs in developing countries...

Persistent link: https://www.econbiz.de/10005404880

Reform of Prescription Drug Reimbursement and Pricing in the German Social Health Insurance Market: A Comparison of Three Scenarios

Gress, Stefan; Niebuhr, Dea; May, Uwe; Wasem, Jurgen - In: PharmacoEconomics 25 (2007) 6, pp. 443-454

: regulation of reimbursement and pricing. We find that centralised regulation of reimbursement and pricing prevails in the 15 …, market approval is nearly always equivalent to reimbursement. Second, manufacturers are free to determine prices but internal … of prescriptions, three reform scenarios are feasible. The first scenario maintains centralised reimbursement and …

Persistent link: https://www.econbiz.de/10005404890

A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand

Ragupathy, Rajan; Aaltonen, Katri; Tordoff, June; … - In: PharmacoEconomics 30 (2012) 11, pp. 1051-1065

licensing bodies and public reimbursement agencies. The present study compares access to licensed and subsidized medicines under …

Persistent link: https://www.econbiz.de/10010579442

The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?

Fattore, Giovanni; Jommi, Claudio - In: PharmacoEconomics 26 (2008) 1, pp. 5-15

principles for reimbursement and pricing, and the use of generic drugs to lower prices. As a result of these changes …

Persistent link: https://www.econbiz.de/10004990333

Does Managed Care Fuel Pharmaceutical Industry Growth?

Murray, Michael D.; Deardorff, Frank W. - In: PharmacoEconomics 14 (1998) 4, pp. 341-348

Managed-care organisations and the pharmaceutical industry have diametrically opposing objectives, though there is hidden common ground. On one hand, most managed-care organisations now want to reduce the cost of drugs or at least maintain drug costs as a hedge against inflation. On the other,...

Persistent link: https://www.econbiz.de/10004990351

Lifestyle Drugs: Determining Their Value and Who Should Pay

Mitrany, Devora - In: PharmacoEconomics 19 (2001) 5, pp. 441-448

Lifestyle drugs are used to alleviate or enhance: 1. lifestyle problems or conditions, regardless of the cause; and 2. health problems for which the underlying cause is in the realm of personal responsibility. It is the particular use of a drug, rather than its inherent properties, that...

Persistent link: https://www.econbiz.de/10005590272

A Stated Preference Binary Choice Experiment to Explore NICE Decision Making

Tappenden, Paul; Brazier, John; Ratcliffe, Julie; … - In: PharmacoEconomics 25 (2007) 8, pp. 685-693

Objective: To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services. Method: A stated preference binary choice experiment was used to explore the preferences...

Persistent link: https://www.econbiz.de/10005590366

Mega-Mergers in the Pharmaceutical Industry: In Whose Interests?

Po, Alain Li Wan - In: PharmacoEconomics 14 (1998) 4, pp. 349-355

Companies merge to achieve economies of scale. In an industry such as the pharmaceutical industry which relies on a high level of investment in research and development, such mergers appear rational. However, it is not at all obvious that a higher level of investment by a smaller number of firms...

Persistent link: https://www.econbiz.de/10005590446